Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 104 participants.

Also called NCT07241338

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Jing Liu (from the registry)
Registry
  • NCT NCT07241338
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07241338. Randomized; no masking; primary purpose treatment. Start 2025-11 (anticipated); primary completion 2026-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity
Acronym
SHOT
Condition
Hypertension
Intervention (Drug)
sacubitril/allisartan
Intervention (Drug)
Amlodipine
Lead sponsor
Jing Liu (class: other)

Record details

Record id
cardio:ct-nct07241338
Content hash
d05bc4281eaa0f8a3bc22a7cc72659fea31341d0228249c41927c8ade9fef678